SureTrader SureTrader
Home > Boards > US Listed > Medical - Drugs >

Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

KTOV RSS Feed
Add KTOV Price Alert      Hide Sticky   Hide Intro
Moderator: Sugarplum, ash111, Millstone, BostonBull1990, TradeFlow, whan7
Search This Board:
Last Post: 12/5/2016 2:59:59 PM - Followers: 132 - Board type: Free - Posts Today: 6
\

 

US Office

1615 Suter’s Lane NW, Washington DC 20007, Tel:  +1-202-965-2215

Israel Office

One Azrieli Center, Round Tower, Tel Aviv 6701101



http://kitovpharma.com/

NQ : $KTOV





Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs
that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.

Kitov is developing combination drug products that treat the pain of osteoarthritis without causing cardiovascular problems.
These drugs will not only not need to be labeled with health warnings, but will actually be labeled as reducing the risk of
cardiovascular events. Kitov’s drugs have the potential to improve the health of millions of patients worldwide.
It is expected that physicians will prefer to prescribe them rather than prescribe two separate drugs, to improve their patients’ health and to reduce their own legal exposure.

Kitov is currently focusing two late-stage drugs. Both contain NSAIDs that are widely consumed throughout the world for treating osteoarthritis.
Each of Kitov’s drugs adds to the NSAID a second drug product that reduces hypertension.

KIT-301: Naproxen combined with anti-hypertension. Ready for phase III clinical trial. New Drug Application (NDA) scheduled
for 20-24 months from start of development.
KIT-302: Celecoxib combined with anti-hypertension. Ready for phase III clinical trial. New Drug Application (NDA) scheduled for 2015.

Osteoarthritis, affecting approximately half of all adults over the age of 50, is a degenerative disease of joints that can cause pain and limit mobility.
Exercise and weight control are important therapies for controlling symptoms, but for many patients medication is the next step in pain treatment.
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly used medications for treating osteoarthritis pain.
However, these medications raise blood pressure (hypertension) and thereby increase the risk of heart attacks, strokes, and death.
This has led the US FDA to require including a black box warning in the labeling of all NSAIDs, warning of these increased cardiovascular risks.




 

Dr. John Paul Waymack – M.D., Sc.D.

Chairman of the Board of Directors and Chief Medical Officer

Dr. Waymack was one of the founders of Kitov Pharmaceuticals and has served as the Chairman of our Board of Directors and Chief Medical Officer since July 2013. Dr. Waymack has over 20 years of experience in the biopharma field. Dr. Waymack is a former academic transplant surgeon and a former FDA medical officer, with over fifteen years of experience in drug development as a consultant to major pharmaceutical companies, including Pfizer, Roche, Pharmacia, Warner Lambert and Searle. During his 10 years of academic career, Dr. Waymack published over 100 scientific essays, mainly in the fields of prostaglandins and immunology. In addition, Dr. Waymack volunteered to the U.S. army, where he was commissioned and served as a Major in the Medical Corp. in the position of Chief of Surgical Research in the U.S. Army’s Institute for Surgical Research. Dr. Waymack was also an associate professor of surgery at the University of Texas Medical Branch and at the University of Medicine and Dentistry of New Jersey.






 

NEWS :

Dec. 17, 2015 :  Kitov Pharmaceuticals Reports Additional Data from its Phase III Trial on the Beneficial Blood Pressure Effects of KIT-302
http://www.prnewswire.com/news-releases/kitov-pharmaceuticals-reports-additional-data-from-its-phase-iii-trial-on-the-beneficial-blood-pressure-effects-of-kit-302-300194664.html


November 20, 2015 : Kitov Pharmaceuticals Holdings Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing
http://www.prnewswire.com/news-releases/kitov-pharmaceuticals-holdings-announces-pricing-of-us-initial-public-offering-and-nasdaq-listing-552301701.html


October 21, 2015 : Kitov Pharma Announces Completion of Patient Recruitment for the Phase III Clinical Trial for KIT-302
http://www.prnewswire.com/news-releases/kitov-pharma-announces-completion-of-patient-recruitment-for-the-phase-iii-clinical-trial-for-kit-302-535035241.html








 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
KTOV
Current Price
Volume:
Bid Ask Day's Range
SureTrader
KTOV News: Post-effective Amendment to Registration Statement (pos Am) 11/28/2016 05:06:42 PM
KTOV News: Post-effective Amendment to Registration Statement (pos Am) 11/28/2016 05:02:45 PM
KTOV News: Securities Registration (foreign Private Issuer) (f-3) 11/28/2016 05:01:52 PM
KTOV News: Report of Foreign Issuer (6-k) 11/02/2016 04:48:44 PM
KTOV News: Report of Foreign Issuer (6-k) 10/27/2016 08:01:16 AM
PostSubject
#4012  Sticky Note GOOD READ 9/2016 PRESENTATION : http://kitovpharma.inve Sugarplum 09/28/16 12:38:22 PM
#3838  Sticky Note KTOV a very professional report (link inside)-"patient population ash111 09/21/16 04:30:30 PM
#3788  Sticky Note KTOV September 13th DD: Market Cap,Cash,sales prediction,Highlights: ash111 09/14/16 12:58:46 PM
#4995   Company has said that the renal study is scottsmith 12/05/16 02:59:59 PM
#4994   It says it will be completed June 2017. DrStockonomics 12/05/16 02:56:02 PM
#4993   Anyone went to the meeting? LearnToTrade 12/05/16 02:01:11 PM
#4992   Looks like the renal study is recruiting: scottsmith 12/05/16 12:29:51 PM
#4991   Agree. I'm not expecting too much. RBNEWS 12/05/16 12:09:59 PM
#4990   Shareholder meeting should be about over. Will we DrStockonomics 12/05/16 11:41:33 AM
#4989   Either that or a partnership with alot of cash!! tmeier 12/04/16 09:14:51 AM
#4988   Of course, that's why I am here. LearnToTrade 12/04/16 12:27:31 AM
#4987   Do you believe 2017 is possible for a mathew633 12/03/16 10:43:01 PM
#4986   I am holding until a buy out. LearnToTrade 12/03/16 03:12:52 PM
#4985   The last PR added about 30 percent to scottsmith 12/03/16 01:41:29 PM
#4984   How much market cap do you expect NDA riverterracekrew 12/03/16 01:11:30 PM
#4983   I expected in Jan'17. LearnToTrade 12/02/16 11:30:09 PM
#4982   worst case Q1 2017 mathew633 12/02/16 11:24:59 PM
#4981   Hopefully, not fun to see our profits LearnToTrade 12/02/16 07:42:21 PM
#4980   Things are going to start to heat up salgovernale69 12/02/16 07:22:24 PM
#4979   That's good to know about Fridays. You scottsmith 12/01/16 05:41:38 PM
#4978   Ok. Thanks. I forgot about that RBNEWS 12/01/16 05:38:25 PM
#4977   TASE trades Sunday - Thursday. salgovernale69 12/01/16 03:07:16 PM
#4976   Pretty sure it's open as I seen no RBNEWS 12/01/16 02:40:46 PM
#4975   It does make sense given the dates. scottsmith 12/01/16 02:23:15 PM
#4974   Upbeat news going into annual meeting on Monday. RBNEWS 12/01/16 02:17:15 PM
#4973   It's already Thursday afternoon but you never know. scottsmith 12/01/16 02:13:34 PM
#4972   Did not see this coming. 1 month RBNEWS 12/01/16 02:01:57 PM
#4971   5 small orders on the ask at the LearnToTrade 12/01/16 10:45:43 AM
#4970   Spread was huge on warrants 1.36/1.48, suddenly I LearnToTrade 12/01/16 10:31:59 AM
#4969   When you hold a bio for more than scottsmith 12/01/16 07:18:50 AM
#4968   What is happening to this stock and to tjguy 12/01/16 07:12:42 AM
#4967   I am really thinking to issue shares to RBNEWS 11/28/16 10:15:03 PM
#4966   Regarding the shelf registration, it's worth noting that salgovernale69 11/28/16 09:39:00 PM
#4965   Agree. This could all be timed out RBNEWS 11/28/16 08:39:40 PM
#4964   I think your long term stability PR is scottsmith 11/28/16 08:19:09 PM
#4963   I will say this, I find the amount RBNEWS 11/28/16 07:53:05 PM
#4962   It's a "shelf offering", which, once approved will Millstone 11/28/16 07:24:17 PM
#4961   http://ih.advfn.com/p.php?pid=nmona&article=73012321 Rymankoly 11/28/16 07:12:39 PM
#4960   Any one see the F3 filing? LearnToTrade 11/28/16 07:06:37 PM
#4959   Amen Doubletree 11/28/16 02:36:28 PM
#4958   Sic transit gloria mundi. migelum 11/28/16 12:50:57 PM
#4957   If you look at the June 28th PR RBNEWS 11/22/16 08:31:45 AM
#4956   Just bad writing. I can't think of scottsmith 11/21/16 11:07:04 AM
#4955   I think they are trying to say it salgovernale69 11/21/16 09:48:24 AM
#4954   Agreed. Anything can happen, but I just tjguy 11/21/16 07:57:45 AM
#4953   Anything can happen. I seem a company only LearnToTrade 11/21/16 07:54:04 AM
#4952   Potential partnership could occur before the NDA submission tjguy 11/21/16 03:26:57 AM
#4949   Here are a few: reminds me of Christmas Sugarplum 11/20/16 12:04:10 PM
#4948   why did you change your id? kei 11/19/16 03:45:22 PM
#4947   sugarplum, do you still own KTOV - KTOVW kei 11/18/16 10:52:09 PM
#4946   KTOV..might pass $4 mark today - my guts feeling! kei 11/18/16 08:07:57 AM
#4945   Yup. 100mg is a half dose. TrumpsVP 11/17/16 10:24:57 PM
#4944   Hope so!! tmeier 11/17/16 05:36:49 PM
PostSubject